25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Acumen Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Acumen Pharmaceuticals Inc together

I guess you are interested in Acumen Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Acumen Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Acumen Pharmaceuticals Inc

I send you an email if I find something interesting about Acumen Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Acumen Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Acumen Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.62
Expected worth in 1 year
$2.57
How sure are you?
10.5%

+ What do you gain per year?

Total Gains per Share
$-1.05
Return On Investment
-65.2%

For what price can you sell your share?

Current Price per Share
$1.61
Expected price per share
$0 - $2.08
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Acumen Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$1.61
Intrinsic Value Per Share
$-18.99 - $-22.54
Total Value Per Share
$-15.37 - $-18.92

2.2. Growth of Acumen Pharmaceuticals Inc (5 min.)




Is Acumen Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$217.2m$204.2m$43.2m17.5%

How much money is Acumen Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$20.4m-$11.9m-$8.4m-41.3%
Net Profit Margin-1,422.2%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Acumen Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#238 / 933

Most Revenue
#676 / 933

Most Profit
#636 / 933

Most Efficient
#733 / 933
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Acumen Pharmaceuticals Inc?

Welcome investor! Acumen Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Acumen Pharmaceuticals Inc.

First you should know what it really means to hold a share of Acumen Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Acumen Pharmaceuticals Inc is $1.61. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Acumen Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Acumen Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.62. Based on the TTM, the Book Value Change Per Share is $-0.26 per quarter. Based on the YOY, the Book Value Change Per Share is $0.35 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Acumen Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.50-30.8%-0.34-21.1%-0.20-12.6%-0.24-14.6%-0.24-14.6%
Usd Book Value Change Per Share-0.45-27.6%-0.26-16.3%0.3521.6%0.1911.8%0.1911.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.45-27.6%-0.26-16.3%0.3521.6%0.1911.8%0.1911.8%
Usd Price Per Share2.48-3.20-4.61-3.76-3.76-
Price to Earnings Ratio-1.25--2.65--5.68--6.85--6.85-
Price-to-Total Gains Ratio-5.57--20.06--23.11--25.85--25.85-
Price to Book Ratio0.69-0.77-1.42-1.05-1.05-
Price-to-Total Gains Ratio-5.57--20.06--23.11--25.85--25.85-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.61
Number of shares621
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.260.19
Usd Total Gains Per Share-0.260.19
Gains per Quarter (621 shares)-162.98118.16
Gains per Year (621 shares)-651.92472.64
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-652-6620473463
20-1304-13140945936
30-1956-1966014181409
40-2608-2618018911882
50-3260-3270023632355
60-3912-3922028362828
70-4563-4574033093301
80-5215-5226037813774
90-5867-5878042544247
100-6519-6530047264720

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.019.00.00.0%0.019.00.00.0%0.019.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%2.014.03.010.5%2.014.03.010.5%2.014.03.010.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.019.00.0%0.00.019.00.0%0.00.019.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%2.014.03.010.5%2.014.03.010.5%2.014.03.010.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Acumen Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.445-0.262-41%0.348-228%0.190-334%0.190-334%
Book Value Per Share--3.6154.120-12%3.400+6%2.378+52%2.378+52%
Current Ratio--10.42619.251-46%23.217-55%25.615-59%25.615-59%
Debt To Asset Ratio--0.1860.153+22%0.039+378%0.359-48%0.359-48%
Debt To Equity Ratio--0.2290.181+27%0.041+463%0.052+339%0.052+339%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--299567904.000387111410.500-23%438444729.000-32%513232869.692-42%513232869.692-42%
Eps---0.495-0.340-31%-0.203-59%-0.235-53%-0.235-53%
Ev To Ebitda Ratio---2.610-5.875+125%-7.737+196%-12.540+380%-12.540+380%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.409-0.280-32%-0.191-53%-0.143-65%-0.143-65%
Free Cash Flow To Equity Per Share---0.410-0.130-68%0.336-222%0.325-226%0.325-226%
Gross Profit Margin--1.0001.000+0%1.0000%1.000+0%1.000+0%
Intrinsic Value_10Y_max---22.536--------
Intrinsic Value_10Y_min---18.989--------
Intrinsic Value_1Y_max---0.998--------
Intrinsic Value_1Y_min---0.979--------
Intrinsic Value_3Y_max---3.958--------
Intrinsic Value_3Y_min---3.760--------
Intrinsic Value_5Y_max---8.077--------
Intrinsic Value_5Y_min---7.415--------
Market Cap96728478.000-54%148997904.000192105160.500-22%276667479.000-46%225994910.842-34%225994910.842-34%
Net Profit Margin----14.2220%-0%-4.3870%-4.3870%
Operating Margin----11.6470%-0%-3.8670%-3.8670%
Operating Ratio---15.936-100%-0%4.927-100%4.927-100%
Pb Ratio0.445-54%0.6860.769-11%1.420-52%1.048-35%1.048-35%
Pe Ratio-0.812+35%-1.251-2.652+112%-5.683+354%-6.850+447%-6.850+447%
Price Per Share1.610-54%2.4803.198-22%4.605-46%3.762-34%3.762-34%
Price To Free Cash Flow Ratio-0.983+35%-1.514-3.510+132%-6.057+300%-6.798+349%-6.798+349%
Price To Total Gains Ratio-3.617+35%-5.571-20.055+260%-23.107+315%-25.853+364%-25.853+364%
Quick Ratio--18.45433.611-45%33.102-44%35.654-48%35.654-48%
Return On Assets---0.111-0.071-36%-0.058-48%-0.116+4%-0.116+4%
Return On Equity---0.137-0.085-38%-0.060-56%-0.041-70%-0.041-70%
Total Gains Per Share---0.445-0.262-41%0.348-228%0.190-334%0.190-334%
Usd Book Value--217202000.000247539000.000-12%204251750.000+6%142885947.368+52%142885947.368+52%
Usd Book Value Change Per Share---0.445-0.262-41%0.348-228%0.190-334%0.190-334%
Usd Book Value Per Share--3.6154.120-12%3.400+6%2.378+52%2.378+52%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--299567904.000387111410.500-23%438444729.000-32%513232869.692-42%513232869.692-42%
Usd Eps---0.495-0.340-31%-0.203-59%-0.235-53%-0.235-53%
Usd Free Cash Flow---24596000.000-16836000.000-32%-11498750.000-53%-8571578.947-65%-8571578.947-65%
Usd Free Cash Flow Per Share---0.409-0.280-32%-0.191-53%-0.143-65%-0.143-65%
Usd Free Cash Flow To Equity Per Share---0.410-0.130-68%0.336-222%0.325-226%0.325-226%
Usd Market Cap96728478.000-54%148997904.000192105160.500-22%276667479.000-46%225994910.842-34%225994910.842-34%
Usd Price Per Share1.610-54%2.4803.198-22%4.605-46%3.762-34%3.762-34%
Usd Profit---29765000.000-20418000.000-31%-11977500.000-60%-14026578.947-53%-14026578.947-53%
Usd Revenue---72500.000-100%-0%149105.263-100%149105.263-100%
Usd Total Gains Per Share---0.445-0.262-41%0.348-228%0.190-334%0.190-334%
 EOD+3 -5MRQTTM+6 -29YOY+7 -255Y+11 -2410Y+11 -24

3.3 Fundamental Score

Let's check the fundamental score of Acumen Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.812
Price to Book Ratio (EOD)Between0-10.445
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than118.454
Current Ratio (MRQ)Greater than110.426
Debt to Asset Ratio (MRQ)Less than10.186
Debt to Equity Ratio (MRQ)Less than10.229
Return on Equity (MRQ)Greater than0.15-0.137
Return on Assets (MRQ)Greater than0.05-0.111
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Acumen Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.677
Ma 20Greater thanMa 501.768
Ma 50Greater thanMa 1002.180
Ma 100Greater thanMa 2002.372
OpenGreater thanClose1.740
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Fundamental data was last updated by Penke on 2025-01-16 11:29:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Acumen Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Acumen Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Acumen Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,422.2%+1,422.2%
TTM-1,422.2%YOY--1,422.2%
TTM-1,422.2%5Y-438.7%-983.5%
5Y-438.7%10Y-438.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--104.6%+104.6%
TTM-1,422.2%-216.4%-1,205.8%
YOY--208.6%+208.6%
5Y-438.7%-353.9%-84.8%
10Y-438.7%-488.0%+49.3%
4.3.1.2. Return on Assets

Shows how efficient Acumen Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Acumen Pharmaceuticals Inc to the Biotechnology industry mean.
  • -11.1% Return on Assets means that Acumen Pharmaceuticals Inc generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Acumen Pharmaceuticals Inc:

  • The MRQ is -11.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.1%TTM-7.1%-4.0%
TTM-7.1%YOY-5.8%-1.3%
TTM-7.1%5Y-11.6%+4.5%
5Y-11.6%10Y-11.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.1%-12.7%+1.6%
TTM-7.1%-13.0%+5.9%
YOY-5.8%-12.3%+6.5%
5Y-11.6%-13.7%+2.1%
10Y-11.6%-15.7%+4.1%
4.3.1.3. Return on Equity

Shows how efficient Acumen Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Acumen Pharmaceuticals Inc to the Biotechnology industry mean.
  • -13.7% Return on Equity means Acumen Pharmaceuticals Inc generated $-0.14 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Acumen Pharmaceuticals Inc:

  • The MRQ is -13.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.7%TTM-8.5%-5.2%
TTM-8.5%YOY-6.0%-2.5%
TTM-8.5%5Y-4.1%-4.4%
5Y-4.1%10Y-4.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.7%-16.8%+3.1%
TTM-8.5%-17.8%+9.3%
YOY-6.0%-16.4%+10.4%
5Y-4.1%-20.6%+16.5%
10Y-4.1%-21.2%+17.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Acumen Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Acumen Pharmaceuticals Inc is operating .

  • Measures how much profit Acumen Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Acumen Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Acumen Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,164.7%+1,164.7%
TTM-1,164.7%YOY--1,164.7%
TTM-1,164.7%5Y-386.7%-778.0%
5Y-386.7%10Y-386.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--193.6%+193.6%
TTM-1,164.7%-321.1%-843.6%
YOY--227.9%+227.9%
5Y-386.7%-373.0%-13.7%
10Y-386.7%-506.1%+119.4%
4.3.2.2. Operating Ratio

Measures how efficient Acumen Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Acumen Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM15.936-15.936
TTM15.936YOY-+15.936
TTM15.9365Y4.927+11.009
5Y4.92710Y4.9270.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.171-2.171
TTM15.9363.250+12.686
YOY-3.231-3.231
5Y4.9274.838+0.089
10Y4.9276.440-1.513
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Acumen Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Acumen Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.43 means the company has $10.43 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Acumen Pharmaceuticals Inc:

  • The MRQ is 10.426. The company is very able to pay all its short-term debts. +2
  • The TTM is 19.251. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.426TTM19.251-8.825
TTM19.251YOY23.217-3.965
TTM19.2515Y25.615-6.364
5Y25.61510Y25.6150.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.4263.610+6.816
TTM19.2513.850+15.401
YOY23.2174.605+18.612
5Y25.6155.895+19.720
10Y25.6156.178+19.437
4.4.3.2. Quick Ratio

Measures if Acumen Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Acumen Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 18.45 means the company can pay off $18.45 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Acumen Pharmaceuticals Inc:

  • The MRQ is 18.454. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 33.611. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ18.454TTM33.611-15.156
TTM33.611YOY33.102+0.509
TTM33.6115Y35.654-2.043
5Y35.65410Y35.6540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.4543.034+15.420
TTM33.6113.355+30.256
YOY33.1024.297+28.805
5Y35.6545.890+29.764
10Y35.6546.434+29.220
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Acumen Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Acumen Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Acumen Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.19 means that Acumen Pharmaceuticals Inc assets are financed with 18.6% credit (debt) and the remaining percentage (100% - 18.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Acumen Pharmaceuticals Inc:

  • The MRQ is 0.186. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.153. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.186TTM0.153+0.034
TTM0.153YOY0.039+0.114
TTM0.1535Y0.359-0.206
5Y0.35910Y0.3590.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1860.341-0.155
TTM0.1530.343-0.190
YOY0.0390.310-0.271
5Y0.3590.366-0.007
10Y0.3590.385-0.026
4.5.4.2. Debt to Equity Ratio

Measures if Acumen Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Acumen Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 22.9% means that company has $0.23 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Acumen Pharmaceuticals Inc:

  • The MRQ is 0.229. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.181. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.229TTM0.181+0.048
TTM0.181YOY0.041+0.140
TTM0.1815Y0.052+0.129
5Y0.05210Y0.0520.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2290.393-0.164
TTM0.1810.429-0.248
YOY0.0410.382-0.341
5Y0.0520.439-0.387
10Y0.0520.489-0.437
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Acumen Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Acumen Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -1.25 means the investor is paying $-1.25 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Acumen Pharmaceuticals Inc:

  • The EOD is -0.812. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.251. Based on the earnings, the company is expensive. -2
  • The TTM is -2.652. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.812MRQ-1.251+0.439
MRQ-1.251TTM-2.652+1.400
TTM-2.652YOY-5.683+3.031
TTM-2.6525Y-6.850+4.198
5Y-6.85010Y-6.8500.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.812-2.247+1.435
MRQ-1.251-2.693+1.442
TTM-2.652-3.214+0.562
YOY-5.683-3.335-2.348
5Y-6.850-6.368-0.482
10Y-6.850-6.692-0.158
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Acumen Pharmaceuticals Inc:

  • The EOD is -0.983. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.514. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.510. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.983MRQ-1.514+0.531
MRQ-1.514TTM-3.510+1.996
TTM-3.510YOY-6.057+2.547
TTM-3.5105Y-6.798+3.288
5Y-6.79810Y-6.7980.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.983-2.993+2.010
MRQ-1.514-3.671+2.157
TTM-3.510-4.037+0.527
YOY-6.057-4.482-1.575
5Y-6.798-8.190+1.392
10Y-6.798-9.383+2.585
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Acumen Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.69 means the investor is paying $0.69 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Acumen Pharmaceuticals Inc:

  • The EOD is 0.445. Based on the equity, the company is cheap. +2
  • The MRQ is 0.686. Based on the equity, the company is cheap. +2
  • The TTM is 0.769. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.445MRQ0.686-0.241
MRQ0.686TTM0.769-0.083
TTM0.769YOY1.420-0.652
TTM0.7695Y1.048-0.279
5Y1.04810Y1.0480.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4451.933-1.488
MRQ0.6862.265-1.579
TTM0.7692.447-1.678
YOY1.4202.454-1.034
5Y1.0483.664-2.616
10Y1.0484.239-3.191
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Acumen Pharmaceuticals Inc.

4.8.1. Institutions holding Acumen Pharmaceuticals Inc

Institutions are holding 78.466% of the shares of Acumen Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30RA Capital Management, LLC24.85370.4271493206300
2024-09-30Franklin Resources Inc5.90730.002335490691814515.3881
2024-09-30Sands Capital Ventures, LLC5.68762.382341707500
2024-09-30BlackRock Inc3.88070.000123315301728698.0082
2024-09-30Rock Springs Capital Management LP3.82830.1856230005900
2024-09-30FMR Inc3.37570.0003202811760140.2974
2024-09-30Vanguard Group Inc3.21910.00011934039370901.9552
2024-09-30Millennium Management LLC3.05390.00221834753-119332-6.1068
2024-09-30Knollwood Investment Advisory LLC2.71060.4324162851000
2024-09-30Alyeska Investment Group, L.P.1.56390.011993960300
2024-09-30LAURION CAPITAL MANAGEMENT LP1.44320.0292867046-311292-26.4179
2024-09-30Geode Capital Management, LLC1.4390.0002864528523956.4515
2024-09-30T. Rowe Price Associates, Inc.1.41420.0002849619-196745-18.8027
2024-09-30Hudson Bay Capital Management LP1.05860.0064636000-34000-5.0746
2024-09-30Pathstone Holdings LLC0.8610.0057517283370607.7172
2024-09-30State Street Corp0.85950.00015164067984118.2885
2024-09-30Jane Street Group LLC0.81160.00034875965990714.0071
2024-09-30Two Sigma Advisers, LLC0.78080.00274691007700019.6378
2024-09-30Two Sigma Investments LLC0.51520.0017309507-1290-0.4151
2024-09-30Northern Trust Corp0.51410.0001308850238762340.6603
Total 67.7783.490540720753+279730+0.7%

4.9.2. Funds holding Acumen Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-11-30Franklin Biotechnology Discv A(acc)USD2.4610.2243147858600
2024-09-30Franklin US Small Cap Growth Equity1.97750.10531188091-12209-1.0172
2024-09-30Franklin Small Cap Growth SMA1.97750.1053118809111880910
2024-11-30Vanguard Total Stock Mkt Idx Inv1.9080.0001114631600
2024-11-30Fidelity Select Health Care1.89750.0345114000000
2024-12-31iShares Russell 2000 ETF1.75560.00251054747-4050-0.3825
2024-11-30Franklin Small Cap Growth Adv1.49170.067389619100
2024-11-30Franklin Biotechnology Discovery A1.37550.215882640000
2024-11-30Fidelity Advisor Health Care I1.16510.03570000000
2024-11-30Vanguard Institutional Extnd Mkt Idx Tr0.78590.000947217200
2024-10-31Fidelity Small Cap Index0.70710.0046424822-304-0.0715
2024-12-31iShares Russell 2000 Value ETF0.64010.0054384547-10752-2.72
2024-12-31State St Russell Sm Cap® Indx SL Cl I0.34150.003720520000
2024-11-30Vanguard Russell 2000 ETF0.32660.003219624451802.7111
2024-11-30Fidelity Extended Market Index0.30670.0009184251-1215-0.6551
2024-11-30Fidelity VIP Health Care Initial0.29960.03518000000
2024-12-31A4Investments SICAV SIF ACCI IlanaA2EURH0.29134.294217500000
2024-09-30Bridgeway Ultra-Small Company Market0.21970.187132000-11000-7.6923
2024-11-30Schwab Small Cap Index0.16460.00329889800
2024-09-30NT R2000 Value Index Fund - NL0.16330.007498082980820
Total 20.25585.335612169638+1251823+10.3%

5.3. Insider Transactions

Insiders are holding 11.236% of the shares of Acumen Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-01-03Daniel Joseph OconnellSELL477781.84
2025-01-03Eric SiemersSELL108591.85
2025-01-03Matt ZugaSELL132351.84
2025-01-03Russell BartonSELL76361.86
2024-01-19Daniel Joseph OconnellSELL152003.47
2024-01-19Derek M MeisnerSELL89333.48
2024-01-18Matt ZugaSELL42423.71
2024-01-18Russell BartonSELL28333.73
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets266,975
Total Liabilities49,773
Total Stockholder Equity217,202
 As reported
Total Liabilities 49,773
Total Stockholder Equity+ 217,202
Total Assets = 266,975

Assets

Total Assets266,975
Total Current Assets207,632
Long-term Assets59,343
Total Current Assets
Cash And Cash Equivalents 33,184
Short-term Investments 167,159
Other Current Assets 7,289
Total Current Assets  (as reported)207,632
Total Current Assets  (calculated)207,632
+/-0
Long-term Assets
Property Plant Equipment 385
Long-term Assets Other 406
Long-term Assets  (as reported)59,343
Long-term Assets  (calculated)791
+/- 58,552

Liabilities & Shareholders' Equity

Total Current Liabilities19,914
Long-term Liabilities29,859
Total Stockholder Equity217,202
Total Current Liabilities
Short-term Debt 129
Accounts payable 2,342
Other Current Liabilities 17,443
Total Current Liabilities  (as reported)19,914
Total Current Liabilities  (calculated)19,914
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)29,859
Long-term Liabilities  (calculated)0
+/- 29,859
Total Stockholder Equity
Common Stock6
Retained Earnings -287,973
Accumulated Other Comprehensive Income 518
Other Stockholders Equity 504,651
Total Stockholder Equity (as reported)217,202
Total Stockholder Equity (calculated)217,202
+/-0
Other
Cash and Short Term Investments 200,343
Common Stock Shares Outstanding 60,080
Liabilities and Stockholders Equity 266,975
Net Debt -3,196
Net Working Capital 187,718
Short Long Term Debt Total 29,988



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
44,429
42,373
72,943
234,849
230,330
220,087
211,678
203,264
196,587
187,864
177,405
286,371
310,125
300,967
288,913
266,975
266,975288,913300,967310,125286,371177,405187,864196,587203,264211,678220,087230,330234,84972,94342,37344,429000
   > Total Current Assets 
0
0
0
44,429
42,103
70,572
204,913
198,661
192,098
191,053
202,560
180,329
144,032
149,538
218,598
246,615
255,831
266,915
207,632
207,632266,915255,831246,615218,598149,538144,032180,329202,560191,053192,098198,661204,91370,57242,10344,429000
       Cash And Cash Equivalents 
0
0
0
43,777
41,407
68,812
135,802
122,162
108,764
111,067
157,540
130,101
77,999
77,248
94,917
66,886
46,930
67,955
33,184
33,18467,95546,93066,88694,91777,24877,999130,101157,540111,067108,764122,162135,80268,81241,40743,777000
       Short-term Investments 
0
0
0
0
0
0
64,162
72,075
80,326
78,844
42,654
47,504
62,410
67,633
120,517
176,636
205,582
192,517
167,159
167,159192,517205,582176,636120,51767,63362,41047,50442,65478,84480,32672,07564,162000000
       Net Receivables 
0
0
0
109
109
109
109
96
158
162
1,867
1,305
0
2,710
0
225
189
106
0
010618922502,71001,3051,86716215896109109109109000
       Other Current Assets 
0
0
0
452
464
1,586
2,293
2,827
1,926
980
499
1,419
3,623
1,944
3,164
2,868
3,130
6,337
7,289
7,2896,3373,1302,8683,1641,9443,6231,4194999801,9262,8272,2931,586464452000
   > Long-term Assets 
0
0
0
0
270
2,371
29,936
31,669
27,989
20,625
704
16,258
43,832
27,867
67,773
63,510
45,136
21,998
59,343
59,34321,99845,13663,51067,77327,86743,83216,25870420,62527,98931,66929,9362,3712700000
       Property Plant Equipment 
0
0
0
0
0
6
13
36
252
280
275
270
218
165
125
503
470
430
385
3854304705031251652182702752802523613600000
       Long Term Investments 
0
0
0
0
0
0
29,910
31,619
27,658
20,001
0
15,837
43,419
27,311
67,270
62,553
44,108
20,908
0
020,90844,10862,55367,27027,31143,41915,837020,00127,65831,61929,910000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
184
0
018400000000000000000
       Other Assets 
0
0
0
0
270
2,365
13
14
79
344
429
0
0
391
0
0
0
0
0
00000391004293447914132,3652700000
       Deferred Long Term Asset Charges 
0
0
0
0
0
2,352
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000002,35200000
> Total Liabilities 
0
0
0
63,020
87,835
179,022
1,489
5,147
3,998
5,159
6,613
7,812
8,779
8,531
6,098
43,152
38,933
44,966
49,773
49,77344,96638,93343,1526,0988,5318,7797,8126,6135,1593,9985,1471,489179,02287,83563,020000
   > Total Current Liabilities 
0
0
0
6,367
31,182
4,518
1,489
5,147
3,936
5,134
6,613
7,812
8,779
8,531
6,098
12,971
8,472
15,367
19,914
19,91415,3678,47212,9716,0988,5318,7797,8126,6135,1343,9365,1471,4894,51831,1826,367000
       Short-term Debt 
0
0
0
0
0
0
0
0
139
142
133
105
67
29
2
1,732
242
250
129
1292502421,7322296710513314213900000000
       Accounts payable 
0
0
0
531
918
2,907
382
1,088
1,219
1,710
2,084
1,640
762
2,026
1,362
1,379
3,079
4,211
2,342
2,3424,2113,0791,3791,3622,0267621,6402,0841,7101,2191,0883822,907918531000
       Other Current Liabilities 
0
0
0
5,836
30,264
1,611
1,107
4,059
2,578
3,282
4,396
6,067
7,950
20
4,734
9,860
5,151
10,906
17,443
17,44310,9065,1519,8604,734207,9506,0674,3963,2822,5784,0591,1071,61130,2645,836000
   > Long-term Liabilities 
0
0
0
56,653
56,653
174,504
382
4,059
62
25
2,217
1,745
829
0
0
30,181
30,461
29,599
29,859
29,85929,59930,46130,181008291,7452,21725624,059382174,50456,65356,653000
       Deferred Long Term Asset Charges 
0
0
0
0
0
2,352
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000002,35200000
       Warrants
0
0
0
0
0
349,008
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000349,00800000
       Deferred Long Term Liability 
0
0
0
0
257
2,352
0
0
0
238
337
0
0
183
0
0
0
0
0
00000183003372380002,3522570000
> Total Stockholder Equity
0
0
0
-18,591
-45,462
-106,079
233,360
225,183
216,089
206,519
196,651
188,775
179,085
168,874
280,273
266,973
262,034
243,947
217,202
217,202243,947262,034266,973280,273168,874179,085188,775196,651206,519216,089225,183233,360-106,079-45,462-18,591000
   Common Stock
0
0
0
0
0
0
4
4
4
4
4
4
4
4
6
6
6
6
6
6666644444444000000
   Retained Earnings Total Equity00000-193,344-181,734-170,427-157,561-146,851-136,700-127,571-119,222-115,32000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
-28
-231
-814
-965
-965
-751
-524
-646
-509
312
-144
-164
518
518-164-144312-509-646-524-751-965-965-814-231-28000000
   Capital Surplus 
0
0
0
0
0
9,241
352,606
352,981
353,599
354,331
355,173
359,949
361,339
362,860
0
0
0
0
0
00000362,860361,339359,949355,173354,331353,599352,981352,6069,24100000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
0
0
0
8,374
8,500
8,174
117,757
352,981
353,599
354,331
355,173
359,949
361,339
362,860
487,077
489,453
499,843
502,313
504,651
504,651502,313499,843489,453487,077362,860361,339359,949355,173354,331353,599352,981117,7578,1748,5008,374000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-42,318
Gross Profit-42,318-42,318
 
Operating Income (+$)
Gross Profit-42,318
Operating Expense-61,138
Operating Income-61,138-103,456
 
Operating Expense (+$)
Research Development42,318
Selling General Administrative18,820
Selling And Marketing Expenses184
Operating Expense61,13861,322
 
Net Interest Income (+$)
Interest Income8,232
Interest Expense-581
Other Finance Cost-581
Net Interest Income8,232
 
Pretax Income (+$)
Operating Income-61,138
Net Interest Income8,232
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-52,371-69,905
EBIT - interestExpense = -52,371
-52,371
-51,790
Interest Expense581
Earnings Before Interest and Taxes (EBIT)-51,790-51,790
Earnings Before Interest and Taxes (EBITDA)-51,606
 
After tax Income (+$)
Income Before Tax-52,371
Tax Provision-0
Net Income From Continuing Ops-48,740-52,371
Net Income-52,371
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses61,138
Total Other Income/Expenses Net8,767-8,232
 

Technical Analysis of Acumen Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Acumen Pharmaceuticals Inc. The general trend of Acumen Pharmaceuticals Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Acumen Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Acumen Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 1.69 < 1.95 < 2.08.

The bearish price targets are: .

Tweet this
Acumen Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Acumen Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Acumen Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Acumen Pharmaceuticals Inc. The current macd is -0.14276226.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Acumen Pharmaceuticals Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Acumen Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Acumen Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Acumen Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAcumen Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Acumen Pharmaceuticals Inc. The current adx is 19.66.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Acumen Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Acumen Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Acumen Pharmaceuticals Inc. The current sar is 1.85410581.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Acumen Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Acumen Pharmaceuticals Inc. The current rsi is 36.68. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Acumen Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAcumen Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Acumen Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Acumen Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Acumen Pharmaceuticals Inc Daily Stochastic Oscillator ChartAcumen Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Acumen Pharmaceuticals Inc. The current cci is -109.79043079.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Acumen Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAcumen Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Acumen Pharmaceuticals Inc. The current cmo is -25.95404271.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Acumen Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAcumen Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Acumen Pharmaceuticals Inc. The current willr is -82.92682927.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Acumen Pharmaceuticals Inc Daily Williams %R ChartAcumen Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Acumen Pharmaceuticals Inc. The current atr is 0.14393039.

Acumen Pharmaceuticals Inc Daily Average True Range (ATR) ChartAcumen Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Acumen Pharmaceuticals Inc. The current obv is 27,683,632.

Acumen Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAcumen Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Acumen Pharmaceuticals Inc. The current mfi is 47.74.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Acumen Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAcumen Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Acumen Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-10STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-13BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-12-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-01-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-01-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Acumen Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Acumen Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.677
Ma 20Greater thanMa 501.768
Ma 50Greater thanMa 1002.180
Ma 100Greater thanMa 2002.372
OpenGreater thanClose1.740
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Acumen Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Acumen Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Acumen Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Acumen Pharmaceuticals Inc

I send you an email if I find something interesting about Acumen Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Acumen Pharmaceuticals Inc.

Receive notifications about Acumen Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.